The Viral Protein Tat Can Inhibit the Establishment of HIV-1 Latency

Journal of Virology

Volumn 86, Issue 6, 2012, Pages 3253-3263

  Donahue, Daniel A ^a,b   Kuhl, Björn D ^a,b,c   Sloan, Richard D ^a   Wainberg, Mark A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSACTIVATOR PROTEIN;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; LEUKEMIA CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSACTIVATION; VIRUS ENTRY; VIRUS INFECTION; VIRUS INHIBITION; VIRUS LATENCY; VIRUS REACTIVATION;

CELL LINE; DOWN-REGULATION; GENE EXPRESSION REGULATION, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS LATENCY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84857948627     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06648-11     Document Type: Article

References (72)

1. Agbottah E, Deng L, Dannenberg LO, Pumfery A, Kashanchi F. 2006. Effect of SWI/SNF chromatin remodeling complex on HIV-1 Tat activated transcription. Retrovirology 3:48.
2. Barboric M, et al. 2007. Tat competes with HEXIM1 to increase the active pool of P-TEFb for HIV-1 transcription. Nucleic Acids Res. 35:2003- 2012.
3. Benkirane M, et al. 1998. Activation of integrated provirus requires histone acetyltransferase. p300 and P/CAF are coactivators for HIV-1 Tat. J. Biol. Chem. 273:24898 -24905.
4. Blazkova J, et al. 2009. CpG methylation controls reactivation of HIV from latency. PLoS Pathog. 5:e1000554.
5. Bosque A, Planelles V. 2009. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 113:58-65.
6. Bowman MC, Archin NM, Margolis DM. 2009. Pharmaceutical approaches to eradication of persistent HIV infection. Expert Rev. Mol. Med. 11:e6.
7. Burnett JC, et al. 2010. Combinatorial latency reactivation for HIV-1 subtypes and variants. J. Virol. 84:5958 -5974.
8. Caputo A, Sodroski JG, Haseltine WA. 1990. Constitutive expression of HIV-1 tat protein in human Jurkat T cells using a BK virus vector. J. Acquir. Immune Defic. Syndr. 3:372-379.
9. Chan JK, Greene WC. 2011. NF-κB/Rel: agonist and antagonist roles in HIV-1 latency. Curr. Opin. HIV AIDS 6:12-18.
10. Chun TW, et al. 1998. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 95:8869-8873.
11. Chun TW, et al. 2007. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J. Infect. Dis. 195:1762-1764.
12. Cohen J. 2011. The emerging race to cure HIV infections. Science 332: 784-785, 787-789.
13. Demarchi F, d'Adda di Fagagna F, Falaschi A, Giacca M. 1996. Activation of transcription factor NF-κB by the Tat protein of human immunodeficiency virus type 1. J. Virol. 70:4427- 4437.
14. Demarchi F, Gutierrez MI, Giacca M. 1999. Human immunodeficiency virus type 1 tat protein activates transcription factor NF-κB through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR. J. Virol. 73:7080 -7086.
15. De Marco A, et al. 2008. Intragenic transcriptional cis-activation of the human immunodeficiency virus 1 does not result in allele-specific inhibition of the endogenous gene. Retrovirology 5:98.
16. Donahue DA, et al. 2010. Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrob. Agents Chemother. 54:1047-1054.
17. Duverger A, et al. 2009. Determinants of the establishment of human immunodeficiency virus type 1 latency. J. Virol. 83:3078 -3093.
18. Emiliani S, et al. 1998. Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line. J. Virol. 72:1666 -1670.
19. Feliu JX, Cubarsi R, Villaverde A. 1998. Optimized release of recombinant proteins by ultrasonication of E. coli cells. Biotechnol. Bioeng. 58: 536-540.
20. Gallastegui E, Millan-Zambrano G, Terme JM, Chavez S, Jordan A. 2011. Chromatin reassembly factors are involved in transcriptional interference promoting HIV latency. J. Virol. 85:3187-3202.
21. Garber ME, et al. 1998. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev. 12:3512-3527.
22. Geeraert L, Kraus G, Pomerantz RJ. 2008. Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu. Rev. Med. 59:487-501.
23. Gianella S, et al. 2011. Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antivir. Ther. 16:535-545.
24. Han Y, et al. 2004. Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J. Virol. 78:6122- 6133.
25. Han Y, et al. 2008. Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe 4:134 -146.
26. Han Y, Wind-Rotolo M, Yang H-C, Siliciano JD, Siliciano RF. 2007. Experimental approaches to the study of HIV-1 latency. Nat. Rev. Microbiol. 5:95-106.
27. He N, et al. 2010. HIV-1 Tat and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coordinated activation of HIV-1 transcription. Mol. Cell 38:428-438.
28. Hottiger MO, Nabel GJ. 1998. Interaction of human immunodeficiency virus type 1 Tat with the transcriptional coactivators p300 and CREB binding protein. J. Virol. 72:8252- 8256.
29. Huang J, et al. 2007. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat. Med. 13:1241-1247.
30. Jenuwein T, Allis CD. 2001. Translating the histone code. Science 293: 1074-1080.
31. Joos B, et al. 2008. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc. Natl. Acad. Sci. U. S. A. 105: 16725-16730.
32. Juven-Gershon T, Kadonaga JT. 2010. Regulation of gene expression via the core promoter and the basal transcriptional machinery. Dev. Biol. 339:225-229.
33. Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E. 2009. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog. 5:e1000495.
34. Kim YK, Mbonye U, Hokello J, Karn J. 2011. T-cell receptor signaling enhances transcriptional elongation from latent HIV proviruses by activating P-TEFb through an ERK-dependent pathway. J. Mol. Biol. 410: 896-916.
35. Krueger BJ, Varzavand K, Cooper JJ, Price DH. 2010. The mechanism of release of P-TEFb and HEXIM1 from the 7SK snRNP by viral and cellular activators includes a conformational change in 7SK. PLoS One 5:e12335.
36. Lassen KG, Ramyar KX, Bailey JR, Zhou Y, Siliciano RF. 2006. Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog. 2:e68.
37. Lenasi T, Contreras X, Peterlin B. 2008. Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe 4:123-133.
38. Mahmoudi T, et al. 2006. The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter. J. Biol. Chem. 281:19960 -19968.
39. Marzio G, Tyagi M, Gutierrez MI, Giacca M. 1998. HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. Proc. Natl. Acad. Sci. U. S. A. 95:13519 -13524.
40. Mazo A, Hodgson JW, Petruk S, Sedkov Y, Brock HW. 2007. Transcriptional interference: an unexpected layer of complexity in gene regulation. J. Cell Sci. 120:2755-2761.
41. Muniz L, Egloff S, Ughy B, Jady BE, Kiss T. 2010. Controlling cellular P-TEFb activity by the HIV-1 transcriptional transactivator Tat. PLoS Pathog. 6:e1001152.
42. Ochsenbauer-Jambor C, Jones J, Heil M, Zammit KP, Kutsch O. 2006. T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication. Biotechniques 40:91-100.
43. Pearson R, et al. 2008. Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency. J. Virol. 82:12291-12303.
44. Peterlin BM, Brogie JE, Price DH. 2012. 7SK snRNA: a noncoding RNA that plays a major role in regulating eukaryotic transcription. Wiley Interdiscip. Rev. RNA 3:92-103.
45. Pomerantz RJ. 2002. Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication. Clin. Infect. Dis. 34:91-97.
46. Pumfery A, et al. 2003. Chromatin remodeling and modification during HIV-1 Tat-activated transcription. Curr. HIV Res. 1:343-362.
47. Reza SM, Rosetti M, Mathews MB, Pe'ery T. 2003. Differential activation of Tat variants in mitogen-stimulated cells: implications for HIV-1 postintegration latency. Virology 310:141-156.
48. Reza SM, et al. 2003. A naturally occurring substitution in human immunodeficiency virus Tat increases expression of the viral genome. J. Virol. 77:8602- 8606.
49. Sastry L, Xu Y, Cooper R, Pollok K, Cornetta K. 2004. Evaluation of plasmid DNA removal from lentiviral vectors by benzonase treatment. Hum. Gene Ther. 15:221-226.
50. Schmid A, et al. 2010. Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection. PLoS One 5:e13310.
51. Schroder AR, et al. 2002. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110:521-529.
52. Sedore SC, et al. 2007. Manipulation of P-TEFb control machinery by HIV: recruitment of P-TEFb from the large form by Tat and binding of HEXIM1 to TAR. Nucleic Acids Res. 35:4347- 4358.
53. Shan L, et al. 2011. Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. J. Virol. 85:5384 -5393.
54. Shearwin KE, Callen BP, Egan JB. 2005. Transcriptional interference-a crash course. Trends Genet. 21:339 -345.
55. Shen L, Siliciano RF. 2008. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J. Allergy Clin. Immunol. 122:22-28.
56. Siddappa NB, et al. 2006. Transactivation and signaling functions of Tat are not correlated: biological and immunological characterization of HIV-1 subtype-C Tat protein. Retrovirology 3:53.
57. Strain MC, et al. 2005. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J. Infect. Dis. 191:1410 -1418.
58. Treand C, et al. 2006. Requirement for SWI/SNF chromatin-remodeling complex in Tat-mediated activation of the HIV-1 promoter. EMBO J. 25:1690 -1699.
59. Trono D, et al. 2010. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 329:174 -180.
60. Tyagi M, Pearson RJ, Karn J. 2010. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J. Virol. 84:6425- 6437.
61. Vardabasso C, Manganaro L, Lusic M, Marcello A, Giacca M. 2008. The histone chaperone protein Nucleosome Assembly Protein-1 (hNAP-1) binds HIV-1 Tat and promotes viral transcription. Retrovirology. 5:8.
62. Wang GP, Ciuffi A, Leipzig J, Berry CC, Bushman FD. 2007. HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res. 17:1186- 1194.
63. Weinberger LS, Burnett JC, Toettcher JE, Arkin AP, Schaffer DV. 2005. Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell 122:169 -182.
64. Weinberger LS, Dar RD, Simpson ML. 2008. Transient-mediated fate determination in a transcriptional circuit of HIV. Nat. Genet. 40:466 - 470.
65. Weinberger LS, Shenk T. 2007. An HIV feedback resistor: autoregulatory circuit deactivator and noise buffer. PLoS Biol. 5:e9.
66. Williams S, Greene W. 2007. Regulation of HIV-1 latency by T-cell activation. Cytokine 39:63-74.
67. Yamamoto N, et al. 2006. Analysis of human immunodeficiency virus type 1 integration by using a specific, sensitive and quantitative assay based on real-time polymerase chain reaction. Virus Genes 32:105-113.
68. Yu JJ, et al. 2008. A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients. Virology 379:78-86.
69. Yukl S, et al. 2009. Latently-infected CD4+T cells are enriched for HIV-1 Tat variants with impaired transactivation activity. Virology 387:98 -108.
70. Zhang H, et al. 2004. Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J. Virol. 78:1718 -1729.
71. Zhou Q, Yik JH. 2006. The yin and yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. Microbiol. Mol. Biol. Rev. 70:646- 659.
72. Zhu Y, et al. 1997. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev. 11:2622-2632.